表皮生长因子受体通路在乳腺癌耐药机制中的研究及应用

表皮生长因子受体在多种肿瘤中存在过度表达.在三苯氧胺耐药(TAM-R)的乳腺癌细胞中表皮生长因子受体(EGFR)的过度表达预示着肿瘤预后不良.研究乳腺癌TAM-R的机制及寻找克服耐药的方案十分重要.已有大量临床前研究显示EGFR信号通路的激活导致乳腺癌细胞产生TAM-R,临床上已有应用EGFR抑制剂于TAM-R乳腺癌的报道,但并非所有患者都能从中获益.EGFR抑制剂的原发或继发耐药是临床上遇到的新难题.

Study and application of epidermal growth factor receptor signaling pathway in tamoxifen resistance of breast cancer

In clinical it has been demonstrated that a lot of malignant tumors exist over-expression of the epidermal growth factor receptor (EGFR) , and the phenomena in the breast cancer which is resistante to Tamoxifen(TAM-R) is associated with poor survival. It is very important to understand the underlying mechanisms of EGFR in the TAM-R breast cancer, and major efforts are now being made to overcome the condition.In some preclinical trials,it has been proved that mechanisms of tamoxifen resistance to endocrine therapy is associated with EGFR signaling activity in hormone-dependent breast cancer cells. There have been reports of the inhibitors to prevent EGFR signaling to treatment of the TAM-R breast cancer in clinical. However, the clinical data demonstrated that not all patients responded to the inhibitor therapy, indicating the existence of an intrinsic or de novo resistance to the drug, which is a new problem.